Xanthones as P-glycoprotein modulators and their impact on drug bioavailability

References

• Silva R, Vilas-Boas V, Carmo H, et al., Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy. Pharmacol Ther. 149(p): 1–123. 2015b.
   PubMedGoogle Scholar
• Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976;455(1):152–62.
   PubMed Web of Science ®Google Scholar
• Aller SG, Yu J, Ward A, et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science. 2009;323(5922):1718–22.
   PubMed Web of Science ®Google Scholar
• Hennessy M, Spiers JP. A primer on the mechanics of P-glycoprotein the multidrug transporter. Pharmacol Res. 2007;55(1):1–15.
   PubMed Web of Science ®Google Scholar
• Sharom FJ, Sharom FJ. The P-glycoprotein multidrug transporter. Essays Biochem. 2011;50(1):161–78.
   PubMed Web of Science ®Google Scholar
• Zhou S-F. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica. 2008;38(7–8):802–32.
   PubMed Web of Science ®Google Scholar
• Mo W, Zhang JT. Human ABCG2: structure, function, and its role in multidrug resistance. Int J Biochem Mol Biol. 2012;3(1):1–27.
   PubMedGoogle Scholar
• Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, et al. P-glycoprotein: from genomics to mechanism. Oncogene. 2003;22(47):7468–85.
   PubMed Web of Science ®Google Scholar
• Amin ML. P-glycoprotein Inhibition for Optimal Drug Delivery. Drug Target Insights. 2013;7(p):27–34.
   PubMedGoogle Scholar
• Sajid A, Lusvarghi S, Chufan EE, et al. Evidence for the critical role of transmembrane helices 1 and 7 in substrate transport by human P-glycoprotein (ABCB1). PLoS One. 2018;13(9):e0204693.
   PubMed Web of Science ®Google Scholar
• Linton KJ. Structure and function of ABC transporters. Physiology (Bethesda). 2007;22(p):122–130.
   PubMedGoogle Scholar
• Vasiliou V, Vasiliou K, Nebert DW. Human ATP-binding cassette (ABC) transporter family. Hum Genomics. 2008;3(3):281–90.
   Google Scholar
• Ito K, Suzuki H, Horie T, et al. Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm Res. 2005;22(10):1559–77.
   PubMed Web of Science ®Google Scholar
• DeGorter MK, Xia CQ, Yang JJ, et al. Drug transporters in drug efficacy and toxicity. Annu Rev Pharmacol Toxicol. 2012;52(1):249–273.
   PubMedGoogle Scholar
• Zamek-Gliszczynski MJ, Hoffmaster KA, Tweedie DJ, et al. Highlights from the International Transporter Consortium second workshop. Clin Pharmacol Ther. 2012;92(5):553–6.
   PubMed Web of Science ®Google Scholar
• Gameiro M, Silva R, Rocha-Pereira C, et al. Cellular Models and In Vitro Assays for the Screening of modulators of P-gp, MRP1 and BCRP. Molecules. 2017;22(4):4.
   Web of Science ®Google Scholar
• Doring B, Petzinger E. Phase 0 and phase III transport in various organs: combined concept of phases in xenobiotic transport and metabolism. Drug Metab Rev. 2014;46(3):261–82.
   PubMed Web of Science ®Google Scholar
• Zhou S-F, Wang -L-L, Di Y, et al. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr Med Chem. 2008;15(20):1981–2039.
   PubMed Web of Science ®Google Scholar
• Ghanem CI, Arias A, Novak A, et al. Acetaminophen-induced stimulation of MDR1 expression and activity in rat intestine and in LS 174T human intestinal cell line. Biochem Pharmacol. 2011;81(2):244–50.
   PubMed Web of Science ®Google Scholar
• Doherty MM, Charman WN. The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism? Clin Pharmacokinet. 2002;41(4):235–53.
   PubMed Web of Science ®Google Scholar
• Schinkel AH. P-Glycoprotein, a gatekeeper in the blood–brain barrier. Adv Drug Deliv Rev. 1999;36(2–3):179–194.
   PubMed Web of Science ®Google Scholar
• Gil-Martins E, Barbosa DJ, Silva V, et al. Dysfunction of ABC transporters at the blood-brain barrier: role in neurological disorders. Pharmacol Ther. 2020;213:107554.
   PubMed Web of Science ®Google Scholar
• de Lange EC. Potential role of ABC transporters as a detoxification system at the blood?CSF barrier. Adv Drug Deliv Rev. 2004;56(12):1793–809.
   PubMed Web of Science ®Google Scholar
• Deeley RG, Westlake C, Cole SP. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev. 2006;86(3):849–99.
   PubMed Web of Science ®Google Scholar
• Ridano ME, Racca AC, Flores-Martin JB, et al. Impact of chlorpyrifos on human villous trophoblasts and chorionic villi. Toxicol Appl Pharmacol. 2017;329(p):26–39.
   PubMedGoogle Scholar
• Gil S, Saura R, Forestier F, et al. P-glycoprotein expression of the human placenta during pregnancy. Placenta. 2005;26(2–3):268–70.
   PubMed Web of Science ®Google Scholar
• Frank MH, Denton MD, Alexander SI, et al. Specific MDR1 P-glycoprotein blockade inhibits human alloimmune T cell activation in vitro. J Immunol. 2001;166(4):2451–9.
   PubMed Web of Science ®Google Scholar
• Silva R, Palmeira A, Carmo H, et al. P-glycoprotein induction in Caco-2 cells by newly synthetized thioxanthones prevents paraquat cytotoxicity. Arch Toxicol. 2015a;89(10):1783–800.
   PubMed Web of Science ®Google Scholar
• Robey RW, Pluchino KM, Hall MD, et al. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer. 2018;18(7):452–464.
   PubMed Web of Science ®Google Scholar
• Tamaki A, Lerano C, Szakacs G, et al. The controversial role of ABC transporters in clinical oncology. Essays Biochem. 2011;50(1):209–232.
   PubMed Web of Science ®Google Scholar
• Fromm MF. Importance of P-glycoprotein at blood–tissue barriers. Trends Pharmacol Sci. 2004;25(8):423–9.
   PubMed Web of Science ®Google Scholar
• Raggers RJ, Vogels I, van Meer G. Multidrug-resistance P-glycoprotein (MDR1) secretes platelet-activating factor. Biochem J. 2001;357(3):859–65.
   PubMedGoogle Scholar
• Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics. 2008;9(1):105–27.
   PubMed Web of Science ®Google Scholar
• Zhang J, Sun T, Liang L, et al. Drug promiscuity of P-glycoprotein and its mechanism of interaction with paclitaxel and doxorubicin. Soft Matter. 2014;10(3):438–45.
   PubMed Web of Science ®Google Scholar
• Palmeira A, Sousa E, H. Vasconcelos M, et al. Three decades of P-gp inhibitors: skimming through several generations and scaffolds. Curr Med Chem. 2012;19(13):1946–2025.
   PubMed Web of Science ®Google Scholar
• Silva R, Carmo H, Dinis-Oliveira R, et al. In vitro study of P-glycoprotein induction as an antidotal pathway to prevent cytotoxicity in Caco-2 cells. Arch Toxicol. 2011;85(4):315–26.
   PubMed Web of Science ®Google Scholar
• Silva R, Carmo H, Vilas-Boas V, et al. Colchicine effect on P-glycoprotein expression and activity: in silico and in vitro studies. Chem Biol Interact. 2014;218(p):50–62.
   PubMedGoogle Scholar
• Rocha-Pereira C, Ghanem CI, Silva R, et al. P-glycoprotein activation by 1-(propan-2-ylamino)-4-propoxy-9H-thioxanthen-9-one (TX5) in rat distal ileum: ex vivo and in vivo studies. Toxicol Appl Pharmacol. 2020;386(p):114832.
   PubMedGoogle Scholar
• Martins E, Silva V, Lemos A, et al., Newly synthesized oxygenated xanthones as potential p-glycoprotein activators: in vitro, ex vivo, and in silico studies. Molecules. 24(4): 707. 2019. .
   Web of Science ®Google Scholar
• Varma MV, Ashokraj Y, Dey CS, et al. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res. 2003;48(4):347–59. .
   PubMed Web of Science ®Google Scholar
• Scotto KW. Transcriptional regulation of ABC drug transporters. Oncogene. 2003;22(47):7496–511.
   PubMed Web of Science ®Google Scholar
• Silva R, Sousa E, Carmo H, et al., Induction and activation of P-glycoprotein by dihydroxylated xanthones protect against the cytotoxicity of the P-glycoprotein substrate paraquat. Arch Toxicol. 88(4): 937–51. 2014. .
   PubMed Web of Science ®Google Scholar
• Sterz K, Möllmann L, Jacobs A, et al. Activators of P-glycoprotein: structure-activity relationships and investigation of their mode of action. ChemMedChem. 2009;4(11):1897–911.
   PubMed Web of Science ®Google Scholar
• Vilas-Boas V, Silva R, Palmeira A, et al. Development of novel rifampicin-derived P-glycoprotein activators/inducers. synthesis, in silico analysis and application in the RBE4 cell model, using paraquat as substrate. PLoS One. 2013;8(8):e74425.
   PubMed Web of Science ®Google Scholar
• Shapiro AB, Ling V. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem. 1997;250(1):130–7.
   PubMedGoogle Scholar
• Shapiro AB, Fox K, Lam P, et al. Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. Eur J Biochem. 1999;259(3):841–50.
   PubMedGoogle Scholar
• Martin C, Berridge G, Higgins CF, et al. Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol. 2000;58(3):624–32.
   PubMed Web of Science ®Google Scholar
• Vilas-Boas V, Silva R, Nunes C, et al. Mechanisms of P-gp inhibition and effects on membrane fluidity of a new rifampicin derivative, 1,8-dibenzoyl-rifampicin. Toxicol Lett. 2013;220(3):259–266.
   PubMed Web of Science ®Google Scholar
• Gomes AS, Brandão P, Sofia Garcia Fernandes C, et al. Drug-like properties and ADME of xanthone derivatives: the antechamber of clinical trials. Curr Med Chem. 2016;23(32):3654–3686.
   PubMed Web of Science ®Google Scholar
• Ahmad I, Shagufta. Recent insight into the biological activities of synthetic xanthone derivatives. Eur J Med Chem. 2016;116(p):267–280.
   PubMedGoogle Scholar
• Luo C-T, Mao -S-S, Liu F-L, et al. Antioxidant xanthones from Swertia mussotii, a high altitude plant. Fitoterapia. 2013;91(p):140–147.
   PubMedGoogle Scholar
• Pinto MM, Sousa ME, Nascimento MS. Xanthone derivatives: new insights in biological activities. Curr Med Chem. 2005;12(21):2517–38.
   PubMed Web of Science ®Google Scholar
• Resende D, Durães F, Maia M, et al. Recent advances in the synthesis of xanthones and azaxanthones. Org Chem Front. 2020;7(19):3027–3066.
   Web of Science ®Google Scholar
• Resende D, Pereira-Terra P, Moreira J, et al. Synthesis of a small library of nature-inspired xanthones and study of their antimicrobial activity. Molecules. 2020;25(10):10.
   Web of Science ®Google Scholar
• Lesch B, Brase S. A short, atom-economical entry to tetrahydroxanthenones. Angew Chem Int Ed Engl. 2004;43(1):115–8.
   PubMed Web of Science ®Google Scholar
• Masters K-S, Brase S. Xanthones from fungi, lichens, and bacteria: the natural products and their synthesis. Chem Rev. 2012;112(7):3717–76.
   PubMed Web of Science ®Google Scholar
• Ruan J, Zheng C, Liu Y, et al. Chemical and biological research on herbal medicines rich in xanthones. Molecules. 2017;22:10.
   Web of Science ®Google Scholar
• Yang C-H, Ma L, WEI Z-P, et al. Advances in isolation and synthesis of xanthone derivatives. Chinese Herbal Medicines. 2012;4(2):87–102.
   Google Scholar
• Fernandes C, Oliveira L, Tiritan ME, et al. Synthesis of new chiral xanthone derivatives acting as nerve conduction blockers in the rat sciatic nerve. Eur J Med Chem. 2012;55(p):1–11.
   PubMedGoogle Scholar
• Negi JS, Bisht VKB,P, Singh P, et al. Naturally Occurring Xanthones: chemistry and Biology. J Appl Chem. 2013;2013:1–9. [ 2013].
   Google Scholar
• Vieira LM, Kijjoa A. Naturally-occurring xanthones: recent developments. Curr Med Chem. 2005;12(21):2413–46.
   PubMed Web of Science ®Google Scholar
• Roberts JC. Naturally Occurring Xanthones.. Chem Rev. 1961;61(6):591–605.
   Web of Science ®Google Scholar
• Klein‐Júnior LC, Campos A, Niero R, et al. Xanthones and Cancer: from Natural Sources to Mechanisms of Action. Chem Biodivers. 2020;17(2):e1900499.
   PubMed Web of Science ®Google Scholar
• Azevedo C, Afonso C, Pinto M. Routes to Xanthones: an Update on the Synthetic Approaches. <![CDATA[Current Organic Chemistry]]>. 2012;16(23):2818–2867.
   Web of Science ®Google Scholar
• Sousa ME, Pinto MM. Synthesis of xanthones: an overview. Curr Med Chem. 2005;12(21):2447–79.
   PubMed Web of Science ®Google Scholar
• Azevedo CM, Afonso C, Pinto M. Magalhaes, and madalena maria magalhaes, routes to xanthones: an update on the synthetic approaches. Curr Org Chem. 2012;16(23):2818–2867.
   Web of Science ®Google Scholar
• Negi JS, Bisht VK, Singh P, et al. Naturally occurring xanthones: chemistry and biology. J Appl Chem. 2013; 2013:621459.
   Google Scholar
• Francik R, Szkaradek N, Zelaszczyk D, et al. ANTIOXIDANT ACTIVITY OF XANTHONE DERIVATIVES. Acta Pol Pharm. 2016;73(6):1505–1509.
   PubMed Web of Science ®Google Scholar
• Jung H-A, Su B-N, Keller WJ, et al. Antioxidant xanthones from the pericarp of garcinia mangostana (Mangosteen). J Agric Food Chem. 2006;54(6):2077–82.
   PubMed Web of Science ®Google Scholar
• Cidade H, Rocha V, Palmeira A, et al. In silico and in vitro antioxidant and cytotoxicity evaluation of oxygenated xanthone derivatives. Arabian J Chem. 2020;13(1):17–26.
   Web of Science ®Google Scholar
• Cheng Y-W, Kang -J-J. Mechanism of vasorelaxation of thoracic aorta caused by xanthone. Eur J Pharmacol. 1997;336(1):23–28.
   PubMed Web of Science ®Google Scholar
• Marona H, Librowski T, Cegla M, et al. Antiarrhythmic and antihypertensive activity of some xanthone derivatives. Acta Pol Pharm. 2008;65(3):383–90.
   PubMed Web of Science ®Google Scholar
• Rajtar G, Zolkowska D, Kleinrok Z, et al. Antiplatelets activity of some xanthone derivatives. Acta Pol Pharm. 1999;56(4):319–24.
   PubMedGoogle Scholar
• Pfister JR, Ferraresi RW, Harrison IT, et al. Xanthone-2-carboxylic acids, a new series of antiallergic substances. J Med Chem. 1972;15(10):1032–1035.
   PubMed Web of Science ®Google Scholar
• Chen L-G, Yang -L-L, Wang -C-C. Anti-inflammatory activity of mangostins from Garcinia mangostana. Food Chem Toxicol. 2008;46(2):688–93.
   PubMed Web of Science ®Google Scholar
• Marona H, Szkaradek N, Karczewska E, et al. Antifungal and antibacterial activity of the newly synthesized 2-xanthone derivatives. Arch Pharm (Weinheim). 2009;342(1):9–18.
   PubMed Web of Science ®Google Scholar
• Yasunaka K, Abe F, Nagayama A, et al. Antibacterial activity of crude extracts from Mexican medicinal plants and purified coumarins and xanthones. J Ethnopharmacol. 2005;97(2):293–9.
   PubMed Web of Science ®Google Scholar
• Nguemeving JR, Azebaze AGB, Kuete V, et al. Laurentixanthones A and B, antimicrobial xanthones from Vismia laurentii. Phytochemistry. 2006;67(13):1341–6.
   PubMed Web of Science ®Google Scholar
• Fukai T, Yonekawa M, Hou A-J, et al. Antifungal agents from the roots of cudrania c ochinchinensis against candida, cryptococcus, and aspergillus species. J Nat Prod. 2003;66(8):1118–1120.
   PubMed Web of Science ®Google Scholar
• Feussi Tala M, Krohn K, Hussain H, et al. Laurentixanthone C: a new antifungal and algicidal xanthone from stem bark of vismia laurentii. Zeitschrift für Naturforschung B. 2007;62:565–568.
   Google Scholar
• Reutrakul V, Anantachoke N, Pohmakotr M, et al. Cytotoxic and anti-HIV-1 caged xanthones from the resin and fruits of garcinia hanburyi. Planta Med. 2006;73(1):33–40.
   PubMed Web of Science ®Google Scholar
• Groweiss A, Cardellina JH, Boyd MR. HIV-inhibitory prenylated xanthones and flavones from maclura t inctoria 1. J Nat Prod. 2000;63(11):1537–9.
   PubMed Web of Science ®Google Scholar
• Xu Z, Huang L, Chen X-H, et al. Cytotoxic prenylated xanthones from the pericarps of garcinia mangostana. Molecules. 2014;19(2):1820–7.
   PubMed Web of Science ®Google Scholar
• Seesom W, Jaratrungtawee A, Suksamrarn S, et al. Antileptospiral activity of xanthones from Garcinia mangostanaand synergy of gamma-mangostin with penicillin G. BMC Complement Altern Med. 2013;13(1): 182–182. 10.1186/1472-6882-13-182.
   PubMedGoogle Scholar
• Al-Massarani SM, El Gamal A, Al-Musayeib N, et al. Phytochemical, antimicrobial and antiprotozoal evaluation of garcinia mangostana pericarp and α-Mangostin, its major xanthone derivative. Molecules. 2013;18(9):10599–608.
   PubMed Web of Science ®Google Scholar
• Wu Y-P, Zhao W, Xia Z-Y, et al. Three novel xanthones from garcinia paucinervis and their anti-TMV activity. Molecules. 2013;18(8):9663–9669.
   PubMed Web of Science ®Google Scholar
• Gnerre C, Thull U, Gaillard P, et al. Natural and synthetic xanthones as monoamine oxidase inhibitors: biological assay and 3D-QSAR. Helvetica Chimica Acta. 2001;84(3):552–570.
   Web of Science ®Google Scholar
• Iikubo K, Ishikawa Y, Ando N, et al. The first direct synthesis of α-mangostin, a potent inhibitor of the acidic sphingomyelinase. Tetrahedron Lett. 2002;43(2):291–293.
   Web of Science ®Google Scholar
• Szkaradek N, Rapacz A, Pytka K, et al. Cardiovascular activity of the chiral xanthone derivatives. Bioorg Med Chem. 2015;23(20):6714–24.
   PubMed Web of Science ®Google Scholar
• Lemos A, Gomes AS, Loureiro JB, et al. Synthesis, biological evaluation, and in silico studies of novel aminated xanthones as potential p53-activating agents. Molecules. 2019;24(10):1975.
   Web of Science ®Google Scholar
• Gomes S, Raimundo L, Soares J, et al. New inhibitor of the TAp73 interaction with MDM2 and mutant p53 with promising antitumor activity against neuroblastoma. Cancer Lett. 2019;446(p):90–102.
   PubMedGoogle Scholar
• Almeida JR, Palmeira A, Campos A, et al. Structure-Antifouling Activity Relationship and Molecular Targets of Bio-Inspired(thio)xanthones. Biomolecules. 2020;10(8):1126.
   Google Scholar
• Resende DISP, Almeida MC, Maciel B, et al. Efficacy, stability, and safety evaluation of new polyphenolic xanthones towards identification of bioactive compounds to fight skin photoaging. Molecules. 2020;25(12):2782.
   Google Scholar
• Silva V, Cerqueira F, Nazareth N, et al. 1,2-Dihydroxyxanthone: effect on A375-C5 melanoma cell growth associated with interference with THP-1 human macrophage activity. Pharm (Basel). 2019;12(2):2.
   Google Scholar
• Rawat B, Singh P, Negi JS. Chemical constituents and biological importance of Swertia: a review. Cur Res Chem. 2011;3(p):1–15.
   Google Scholar
• Jagetia GC, Venkatesha VA. Mangiferin, a glucosylxanthone, protects against the radiation-induced micronuclei formation in the cultured human peripheral blood lymphocytes. Int Congress Series. 2005;1276(p):195–196.
   Google Scholar
• Leiro J, Arranz JA, Yáñez M, et al. Expression profiles of genes involved in the mouse nuclear factor-kappa B signal transduction pathway are modulated by mangiferin. Int Immunopharmacol. 2004;4(6):763–78.
   PubMed Web of Science ®Google Scholar
• Jastrzebska-Wiesek M, Czarnecki R, Marona H. The anticonvulsant, local anesthetic and hemodynamic properties of some chiral aminobutanol derivatives of xanthone. Acta Pol Pharm. 2008;65(5):591–600.
   PubMed Web of Science ®Google Scholar
• Ali M, Latif A, Zaman K, et al. Anti-ulcer xanthones from the roots of hypericum oblongifolium wall. Fitoterapia. 2014;95(p):258–265.
   PubMedGoogle Scholar
• Li H, MIYAHARA T, TEZUKA Y, et al. The effect of kampo formulae on bone resorption in vitro and in vivo. I. Active constituents of Tsu-kan-gan. Biol Pharm Bull. 1998;21(12):1322–1326.
   PubMed Web of Science ®Google Scholar
• Perrucci S, Fichi G, Buggiani C, et al. Efficacy of mangiferin against Cryptosporidium parvum in a neonatal mouse model. Parasitol Res. 2006;99(2):184–8.
   PubMed Web of Science ®Google Scholar
• Ryu HW, Curtis-Long MJ, Jung S, et al. Xanthones with neuraminidase inhibitory activity from the seedcases of Garcinia mangostana. Bioorg Med Chem. 2010;18(17):6258–64.
   PubMed Web of Science ®Google Scholar
• Riscoe MV, Winter RW, Ignatushchenko M. Xanthones as antimalarial agents: stage specificity. Am J Trop Med Hyg. 2000;62(1):77–81.
   PubMed Web of Science ®Google Scholar
• Quan G-H, Oh S-R, Kim J-H, et al. Xanthone constituents of the fruits of garcinia mangostana with anticomplement activity. Phytother Res. 2010;24(10):1575–1577.
   PubMed Web of Science ®Google Scholar
• Shan T, Ma Q, Guo K, et al. Xanthones from mangosteen extracts as natural chemopreventive agents: potential anticancer drugs. Curr Mol Med. 2011;11(8):666–77.
   PubMed Web of Science ®Google Scholar
• Estudante M, Morais JG, Soveral G, et al. Intestinal drug transporters: an overview. Adv Drug Deliv Rev. 2013;65(10):1340–56.
   PubMed Web of Science ®Google Scholar
• Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A. 1987;84(21):7735–8.
   PubMed Web of Science ®Google Scholar
• Chen P, Chen H, Zang X, et al. Expression of efflux transporters in human ocular tissues. Drug Metab Dispos. 2013;41(11):1934–48.
   PubMed Web of Science ®Google Scholar
• Carey SS, Gleason-Guzman M, Gokhale V, et al. Psorospermin structural requirements for P-glycoprotein resistance reversal. Mol Cancer Ther. 2008;7(11):3617–3623.
   PubMed Web of Science ®Google Scholar
• Chae SW, Lee J, Park JH, et al. Intestinal P-glycoprotein inhibitors, Benzoxanthone Analogues. J Pharm Pharmacol. 2018;70(2):234–241.
   Google Scholar
• Chieli E, Romiti N, Rodeiro I, et al. In vitro effects of Mangifera indica and polyphenols derived on ABCB1/P-glycoprotein activity. Food Chem Toxicol. 2009;47(11):2703–2710.
   PubMed Web of Science ®Google Scholar
• Chieli E, Romiti N, Rodeiro I, et al. In vitro modulation of ABCB1/P-glycoprotein expression by polyphenols from Mangifera indica. Chem Biol Interact. 2010;186(3):287–294.
   PubMed Web of Science ®Google Scholar
• Kaewpiboon C, Boonnak N, Yawut N, et al. Caged-xanthone from Cratoxylum formosum sspruniflorum inhibits malignant cancer phenotypes in multidrug-resistant human A549 lung cancer cells through down-regulation of NF-κB. Bioorg Med Chem. 2019;27(12):2368–2375.
   PubMed Web of Science ®Google Scholar
• Louisa M, Soediro TM, Suyatna FD. In vitro modulation of P-glycoprotein, MRP-1 and BCRP expression by mangiferin in doxorubicin-treated MCF-7 cells. Asian Pac J Cancer Prev. 2014;15(4):1639–42.
   PubMedGoogle Scholar
• Tolosa L, Rodeiro I, Donato MT, et al. Multiparametric evaluation of the cytoprotective effect of the Mangifera indica L. Stem Bark Extract and Mangiferin in HepG2 Cells. J Pharm Pharmacol. 2013;65(7):1073–1082.
   Google Scholar
• Wang L-H, Yang J-Y, Yang S-N, et al. Suppression of NF-κB signaling and p-glycoprotein function by gambogic acid synergistically potentiates adriamycin -induced apoptosis in lung cancer. Curr Cancer Drug Targets. 2014;14(1):91–103.
   PubMed Web of Science ®Google Scholar
• Wang S, Wang L, Chen M, et al. Gambogic acid sensitizes resistant breast cancer cells to doxorubicin through inhibiting P-glycoprotein and suppressing survivin expression. Chem Biol Interact. 2015;235(p):76–84.
   PubMedGoogle Scholar
• Wang S, Yang Y, Wang Y, et al. Gambogic acid-loaded pH-sensitive mixed micelles for overcoming breast cancer resistance. Int J Pharm. 2015;495(2):840–848.
   PubMed Web of Science ®Google Scholar
• Wang X, Deng R, Lu Y, et al. Gambogic acid as a non-competitive inhibitor of ATP-binding cassette transporter B1 reverses the multidrug resistance of human epithelial cancers by promoting ATP-binding cassette transporter B1 protein degradation. Basic Clin Pharmacol Toxicol. 2013;112(1):25–33.
   Google Scholar
• Zhou Y, Wang R, Chen B, et al. Daunorubicin and gambogic acid coloaded cysteamine-CdTe quantum dots minimizing the multidrug resistance of lymphoma in vitro and in vivo. Int J Nanomed. 2016;11(p):5429–5442.
   PubMedGoogle Scholar
• Palmeira A, Vasconcelos MH, Paiva A, et al. Dual inhibitors of P-glycoprotein and tumor cell growth: (Re)discovering thioxanthones. Biochem Pharmacol. 2012;83(1):57–68.
   PubMed Web of Science ®Google Scholar
• Huang J, Zhu X, Wang H, et al. Role of gambogic acid and NaI131 in A549/DDP cells. Oncol Lett. 2017;13(1):37–44.
   PubMed Web of Science ®Google Scholar
• Sousa E, Palmeira A, Cordeiro AS, et al. Bioactive xanthones with effect on P-glycoprotein and prediction of intestinal absorption. Med Chem Res. 2013;22(5):2115–2123.
   Web of Science ®Google Scholar
• Tian F, Dahmani FZ, Qiao J, et al. A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer. Acta Biomater. 2018;75(p):398–412.
   PubMedGoogle Scholar
• Xu Q, Guo J, Chen W. Gambogenic acid reverses P-glycoprotein mediated multidrug resistance in HepG2/Adr cells and its underlying mechanism. Biochem Biophys Res Commun. 2019;508(3):882–888.
   PubMed Web of Science ®Google Scholar
• Tchamo DN, Dijoux-Franca M-G, Mariotte A-M, et al. Prenylated xanthones as potential P-glycoprotein modulators. Bioorg Med Chem Lett. 2000;10(12):1343–5.
   PubMed Web of Science ®Google Scholar
• Ye D, Zhou X, Pan H, et al. Establishment and characterization of an HPV16 E6/E7-expressing oral squamous cell carcinoma cell line with enhanced tumorigenicity. Med Oncol. 2011;28(4):1331–1337.
   PubMed Web of Science ®Google Scholar
• Paiva AM, Sousa ME, Camões A, et al. Prenylated xanthones: antiproliferative effects and enhancement of the growth inhibitory action of 4-hydroxytamoxifen in estrogen receptor-positive breast cancer cell line. Med Chem Res. 2012;21(5):552–558.
   Web of Science ®Google Scholar
• Pedro M, Cerqueira F, Sousa ME, et al. Xanthones as inhibitors of growth of human cancer cell lines and Their effects on the proliferation of human lymphocytes In Vitro. Bioorg Med Chem. 2002;10(12):3725–3730.
   PubMed Web of Science ®Google Scholar
• Sousa E, Silva A, Pinto M, et al. Isomeric Kielcorins and Dihydroxyxanthones: synthesis, Structure Elucidation, and Inhibitory Activities of Growth of Human Cancer Cell Lines and on the Proliferation of Human Lymphocytes In Vitro. Helvetica Chimica Acta. 2002;85(9):2862–2876.
   Web of Science ®Google Scholar
• Palmeira A, Paiva A, Sousa E, et al. Insights into the In Vitro Antitumor Mechanism of Action of a New Pyranoxanthone. Chem Biol Drug Des. 2010;76(1):43–58.
   Google Scholar
• Kim HG, Hien TT, Han EH, et al. Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation. Br J Pharmacol. 2011;162(5):1096–1108.
   Google Scholar
• Sun J, Yeung CA, Co NN, et al. Clitocine reversal of P-glycoprotein associated multi-drug resistance through down-regulation of transcription factor NF-κB in R-HEPG2 cell line. Plos One. 2012;7(8):e40720.
   PubMed Web of Science ®Google Scholar
• Silva V, Gil-Martins E, Rocha-Pereira C, et al. Oxygenated xanthones as P-glycoprotein modulators at the intestinal barrier: in vitro and docking studies. Med Chem Res. 2020;29(6):1041–1057.
   Web of Science ®Google Scholar
• Boonyong C, Pattamadilok C, Suttisri R, et al. Benzophenones and xanthone derivatives from Garcinia schomburgkiana -induced P-glycoprotein overexpression in human colorectal Caco-2 cells via oxidative stress-mediated mechanisms. Phytomedicine. 2017;27(p):8–14.
   PubMedGoogle Scholar
• Paiva AM, Pinto MM, Sousa E. A Century of Thioxanthones: through Synthesis and Biological Applications. <![CDATA[Current Medicinal Chemistry]]>. 2013;20(19):2438–2457.
   PubMed Web of Science ®Google Scholar
• Hageman HJ. Photoinitiators for free radical polymerization. Prog Org Coat. 1985;13(2):123–150.
   Web of Science ®Google Scholar
• Yilmaz G, Tuzun A, Yagci Y. Thioxanthone–carbazole as a Visible Light Photoinitiator for Free Radical Polymerization. Journal of Applied Chemistry. 2010;48(22):5120–5125.
   Google Scholar
• Archer S, Pica-Mattoccia L, Cioli D, et al. The preparation, antischistosomal and antitumor activity of hycanthone and some of its congeners. Evidence for the mode of action of hycanthone. J Med Chem. 1988;31(1):254–260.
   PubMed Web of Science ®Google Scholar
• Bessa LJ, Palmeira A, Gomes AS, et al. Synergistic effects between thioxanthones and oxacillin against methicillin-resistant staphylococcus aureus. Microb Drug Resist. 2015;21(4):404–15.
   PubMed Web of Science ®Google Scholar
• Harfenist M, Joseph DM, Spence SC, et al. selective inhibitors of monoamine oxidase. 4. 1 SAR of Tricyclic N -methylcarboxamides and congeners binding at the tricyclics’ hydrophilic binding site. J Med Chem. 1997;40(16):2466–73.
   PubMed Web of Science ®Google Scholar
• Woo S-W, Kang D-H, Kim J-S, et al. Synthesis, Cytotoxicity and Topoisomerase II Inhibition Study of New Thioxanthone Analogues. Bull Korean Chem Soc. 2008;29(p):471–474.
   Google Scholar
• Kostakis IK, Pouli N, Marakos P, et al. Synthesis, cytotoxic activity, NMR study and stereochemical effects of some new pyrano[3,2- b]thioxanthen-6-ones and Pyrano[2,3- c]thioxanthen-7-ones. Bioorg Med Chem. 2001;9(11):2793–2802.
   PubMed Web of Science ®Google Scholar
• Palmeira A, Sousa ME, Fernandes MX, et al. Multidrug resistance reversal effects of aminated thioxanthones and interaction with cytochrome P450 3A4. J Pharm Pharm Sci. 2011;15(1):31–45.
   Web of Science ®Google Scholar
• Del Rowe JD, Bello J, Mitnick R, et al. Accelerated regression of brain metastases in patients receiving whole brain radiation and the topoisomerase II inhibitor, lucanthone. Int J Radiat Oncol Biol Phys. 1999;43(1):89–93.
   PubMed Web of Science ®Google Scholar
• Mendez F, Goldman J, Bases R. Abasic Sites in DNA of HeLa Cells Induced by Lucanthone1. Cancer Invest. 2002;20(7–8):983–991.
   PubMed Web of Science ®Google Scholar
• Carew JS, Espitia CM, Esquivel JA, et al. Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis. J Biol Chem. 2011;286(8):6602–6613.
   PubMed Web of Science ®Google Scholar
• Lopes A, Martins E, Silva R, et al. Chiral Thioxanthones as Modulators of P-glycoprotein: synthesis and Enantioselectivity Studies. Molecules. 2018;23(3):3.
   Web of Science ®Google Scholar
• Barbosa J, Lima R, Sousa D, et al. Screening a Small Library of Xanthones for Antitumor Activity and Identification of a Hit Compound which Induces Apoptosis. Molecules. 2016;21(1):81.
   PubMed Web of Science ®Google Scholar
• Lima RT, Sousa D, Paiva A, et al. Modulation of Autophagy by a Thioxanthone Decreases the Viability of Melanoma Cells. Molecules. 2016;21(10):10.
   Web of Science ®Google Scholar
• Chae SW, Woo S, Park JH, et al. Xanthone analogues as potent modulators of intestinal P-glycoprotein. Eur J Med Chem. 2015;93(p):237–245.
   PubMedGoogle Scholar
• Rocha-Pereira C, Silva V, Costa VM, et al. Histological and toxicological evaluation, in rat, of a P-glycoprotein inducer and activator: 1-(propan-2-ylamino)-4-propoxy-9H-thioxanthen-9-one (TX5). Excli J. 2019;18(p):697–722.
   PubMedGoogle Scholar